Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
ANGLE plc ( (GB:AGL) ) has issued an update.
ANGLE plc has announced significant findings from a Phase 1 clinical trial using its Parsortix system to identify patients with highly metastatic CTC clusters for targeted cancer treatment. The study demonstrates the potential of a repurposed drug, digoxin, to reduce CTC cluster size, paving the way for new treatments targeting metastasis. This advancement could significantly improve patient outcomes by enabling more effective targeting of metastatic processes, highlighting ANGLE’s crucial role in the development of novel cancer therapies.
More about ANGLE plc
ANGLE plc is a leading company in the liquid biopsy industry, providing innovative circulating tumor cell (CTC) solutions for research, drug development, and clinical oncology. The company focuses on clinical services and diagnostic products, utilizing its Parsortix system for CTC harvesting and analysis, which is FDA cleared and patent protected.
YTD Price Performance: 17.07%
Average Trading Volume: 1,155,827
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £38.7M
Learn more about AGL stock on TipRanks’ Stock Analysis page.
